Related Experiment Video
Updated: Nov 20, 2025
06:21
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
983
[Two Cases of Alpha-Fetoprotein Producing Gastric Cancer]
Sho Tazuma1, Naokuni Tatsumoto, Takeshi Kobayashi
1Dept. of Surgery, Miyoshi Central Hospital.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|January 20, 2021
Summary
Alpha-fetoprotein (AFP) producing gastric cancer presents unique challenges. Outcomes vary significantly, with one patient experiencing rapid metastasis and another achieving long-term survival with multimodal therapy.
Area of Science:
- Gastroenterology
- Oncology
- Pathology
Background:
- Esophagogastric junction cancer and distal gastric cancer are distinct clinical entities.
- Alpha-fetoprotein (AFP) producing gastric cancer is a rare subtype with potentially aggressive behavior.
Observation:
- Two cases of alpha-fetoprotein (AFP) producing gastric cancer are presented.
- Case 1: A 51-year-old man with esophagogastric junction cancer developed lung metastasis post-gastrectomy, succumbing to the disease within 4 months despite chemotherapy.
- Case 2: A 79-year-old man with distal gastric cancer developed lymph node metastasis post-gastrectomy but survived over 9 years with chemotherapy and radiation therapy.
Findings:
- Outcomes for AFP producing gastric cancer are highly variable.
- Aggressive metastatic disease can occur early after surgical resection.
- Multimodal treatment approaches may improve survival in select patients.
Implications:
- AFP producing gastric cancer warrants further investigation into its unique biology and treatment strategies.
- Early detection and tailored therapeutic interventions are crucial for improving patient prognosis.
- This rare subtype highlights the need for personalized medicine in gastric oncology.
